Olaparib hydroxybenzoic acid cocrystals and their pharmaceutical use
US12049452B2 · kind B2 · utility
0Cited by
0References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 10, 2022 |
| Grant date | Jul 30, 2024 |
| Priority date | — |
| Expiry date | Nov 10, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to new 1:1 olaparib:hydroxybenzoic acid cocrystals. The invention also relates to new 2:1 olaparib:hydroxybenzoic acid cocrystals which may contain no water (anhydrous) or may optionally be hydrated. The invention also relates to pharmaceutical compositions containing an olaparib hydroxybenzoic acid cocrystal of the invention and a pharmaceutically acceptable carrier. The olaparib hydroxybenzoic acid cocrystals of the invention may be useful for the treatment of diseases that benefit from inhibition of poly (ADP-ribose) polymerase (PARP).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.